SCHEMBL538250

SCHEMBL538250

C(=C/c1cc2ccccc2[nH]1)\c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.58
MAPT P10636 1/20 0.56
IDO1 P14902 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2D6 P10635 1/20 0.56
MAPK1 P28482 1/20 0.56
CYP2C19 P33261 1/20 0.56
BCHE P06276 1/20 0.51
ACHE P22303 1/20 0.51
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HSP90AA1 P07900 1/20 0.47
PKM P14618 1/20 0.47
HPGD P15428 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL538252 1.00 CYP2A6 (0.58) CYP2A6MAPTIDO1NPSR1CYP1A2
SCHEMBL9834598 1.00 CYP2A6 (0.58) CYP2A6MAPTIDO1NPSR1CYP1A2
SCHEMBL2458425 0.90 CYP2A6 (0.69) CYP2A6MAPTIDO1NPSR1CYP1A2
SCHEMBL2458423 0.90 CYP2A6 (0.69) CYP2A6MAPTIDO1NPSR1CYP1A2
SCHEMBL26467449 0.89 CYP2A6 (0.55) CYP2A6MAPTIDO1NPSR1CYP1A2
SCHEMBL17433423 0.86 CYP2A6 (0.51) CYP2A6MAPTIDO1NPSR1CYP1A2
SCHEMBL14386993 0.86 MAPT (0.53) CYP2A6MAPTIDO1NPSR1CYP1A2
SCHEMBL18666088 0.86 CYP2A6 (0.51) CYP2A6MAPTIDO1NPSR1CYP1A2
SCHEMBL17433424 0.83 AKR1C3 (0.55) CYP2A6MAPTIDO1NPSR1CYP1A2
SCHEMBL1177092 0.82 CYP2A6 (0.60) CYP2A6MAPTIDO1NPSR1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102762555-A Fluorescent cell markers BEATRIZ BEATRIZ ZAYAS 2012-10-31 CN claimed
US-8124770-B2 Fluorescent cellular markers NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-02-28 US claimed
US-20100256378-A1 FLUORESCENT CELLULAR MARKERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-10-07 US claimed
US-6403239-B2 MONOMER CONTAINING PHOTOLUMINESCENCE COMPOUND BAYER AG (DE) 2002-06-11 US claimed
EP-0767234-B1 (Co)polymers based on vinyl monomers and their use in electroluminescent devices BAYER AG (DE) 2001-12-19 EP claimed
EP-0728775-B1 (Co)polymers based on vinyl monomers and their use in electroluminescent devices BAYER AG (DE) 2001-10-04 EP claimed
US-20010026879-A1 (Co)polymers based on vinyl units and use thereof in electroluminescent devices CHEN YUN (DE) 2001-10-04 US claimed
US-6114463-A Copolymers based on vinyl units and their use in electroluminescent devices BAYER AG (DE) 2000-09-05 US claimed
US-6075106-A (Co)polymers based on vinyl units and use thereof in electroluminescent devices D-51368 BAYER AG (DE) 2000-06-13 US claimed
US-5891975-A (Co)polymers based on vinyl units and use thereof in electroluminescent devices BAYER AKTIENGESELLSCHAFT (DE) 1999-04-06 US claimed
EP-0825207-A2 (Co)Polymers based on vinyl monomers and their use in electroluminescent devices BAYER AG (DE) 1998-02-25 EP claimed
EP-0767234-A2 (Co)polymers based on vinyl monomers and their use in electroluminescent devices BAYER AG (DE) 1997-04-09 EP claimed
EP-0735055-A2 Vinyl polymers and copolymers and their use in electroluminescent devices BAYER AG (DE) 1996-10-02 EP claimed
EP-0728775-A2 (Co)polymers based on vinyl monomers and their use in electroluminescent devices BAYER AG (DE) 1996-08-28 EP claimed
US-20240066023-A1 Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition SISTEMA UNIVERSITARIO ANA G. MENDEZ, INC. (US) 2024-02-29 US disclosed
US-11786520-B2 Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition SISTEMA UNIV ANA G MENDEZ INC (US) 2023-10-17 US disclosed
US-11311531-B2 Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition SISTEMA UNIV ANA G MENDEZ INC (US) 2022-04-26 US disclosed
EP-0362695-B1 PYRROLOCARBAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS GÖDECKE AKTIENGESELLSCHAFT (DE) 1991-04-03 EP disclosed
EP-0362695-A1 Pyrrolocarbazole derivatives, processes for their preparation and their use as medicaments GÖDECKE AKTIENGESELLSCHAFT (DE) 1990-04-11 EP disclosed
US-4912107-A Pyrrolocarbazole derivatives, compositions containing them, and methods for using them GOEDECKE AKTIENGESELLSCHAFT (DE) 1990-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11786520-B2 Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition AHNAK, RECQL, NBAS CYP2A6 2547/4885MAPT 4399/4885IDO1 1195/4885
US-11311531-B2 Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition RECQL, AHNAK, NDUFS1 CYP2A6 2387/4885MAPT 4449/4885IDO1 1003/4885
US-20100256378-A1 FLUORESCENT CELLULAR MARKERS AIFM1, CASP3, BAX CYP2A6 4465/4885MAPT 3510/4885IDO1 3361/4885
US-20240066023-A1 Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition AHNAK, RECQL, NBAS CYP2A6 2547/4885MAPT 4399/4885IDO1 1195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.